MANE

Veradermics, Incorporated

Veradermics, Incorporated (MANE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (C-). The rating has held at C for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -52.0
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 20.0%
Price Return 12M 258.4%
Catalyst Signal 0.00
Market Cap $5.7B
TTM Revenue N/A
Price / Sales N/A
ROE -23.1%

Historical Factor Score Progression

Held C for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C- (2.0) C- (2.1) B- (3.0) C+ (2.6) C (2.4)
2026-11-06 C+ (2.5) C- (1.9) D- (0.8) C+ (2.8) C+ (2.7) C (2.2)
2026-10-30 C+ (2.5) C- (1.9) D- (0.8) B (3.2) C+ (2.7) C (2.2)
2026-10-23 C+ (2.5) C- (1.9) D- (0.8) B (3.4) C+ (2.6) C (2.3)
2026-10-16 C+ (2.5) C- (1.9) D- (0.8) B- (3.1) C+ (2.6) C (2.2)
Page 1 of 4